Open-label trial and randomized, double-blind, placebo-controlled, crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies.
Mikako Ito, Tohru Ibi, Ko Sahashi, Masashi Ichihara, Masafumi Ito, Kinji Ohno · Medical gas research · 2011
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 0 patients with progressive muscular dystrophy (PMD), less prominent effects with the double-blind trial compared to the open-label trial were likely due to a lower amount of administered hydrogen and a shorter observation period, which implies a threshold effect or a dose-response effect of hydrogen. These findings add human evidence supporting molecular hydrogen's therapeutic potential for metabolic syndrome.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 0 patients with progressive muscular dystrophy (PMD). Less prominent effects with the double-blind trial compared to the open-label trial were likely due to a lower amount of administered hydrogen and a shorter observation period, which implies a threshold effect or a dose-response effect of hydrogen.
What the Researchers Studied
The researchers studied 0 patients with progressive muscular dystrophy (PMD). The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 12 weeks. Less prominent effects with the double-blind trial compared to the open-label trial were likely due to a lower amount of administered hydrogen and a shorter observation period, which implies a threshold effect or a dose-response effect of hydrogen.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for metabolic syndrome and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled, crossover human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 0 patients with progressive muscular dystrophy (PMD). The reported sample size was 5. The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The reported treatment duration was 12 weeks.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.